Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI)

Area of Science:

• Oncology
• Immunology
• Medicinal Chemistry

Background:

• The TGFβ-TGFβR signaling pathway is implicated in tumor progression by promoting immunosuppression and epithelial-mesenchymal transition (EMT).
• Inhibiting TGFβR presents a therapeutic strategy to enhance anti-tumor immune responses.

Purpose of the Study:

• To identify and optimize novel small molecule inhibitors targeting TGFβ receptor I (TGFβRI).
• To evaluate the efficacy of these inhibitors in blocking SMAD phosphorylation and their potential in cancer immunotherapy.

Main Methods:

• Structure-based drug design was employed to optimize a novel pyrrolotriazine chemotype.
• In vitro assays were used to determine binding affinity (Ki), residence time (T1/2), and cellular potency (IC50) against SMAD phosphorylation.
• In vivo studies and experiments with primary human T cells assessed the inhibition of TGFβ-stimulated phospho-SMAD.

Main Results:

• Optimized pyrrolotriazine inhibitors demonstrated high binding affinity (Ki apparent = 0.14 nM) and long residence time (T1/2 > 120 min).
• Potent inhibition of SMAD phosphorylation was achieved with an IC50 of 24 nM in cellular assays.
• Several analogs effectively inhibited SMAD phosphorylation both in vitro and in vivo, and in primary human T cells.

Conclusions:

• Novel heterobicyclic inhibitors of TGFβRI were successfully identified and optimized.
• These inhibitors show significant potential for enhancing anti-tumor immunity by blocking the TGFβ-SMAD signaling pathway.
• The developed compounds represent promising candidates for further development in cancer immunotherapy.